Related Experiment Video

Updated: May 27, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Therapeutic potential of KCa3.1 blockers: recent advances and promising trends

Heike Wulff1, Neil A Castle

  • 1University of California, Davis, CA, USA. hwulff@ucdavis.edu

Expert Review of Clinical Pharmacology
|November 25, 2011
PubMed

Insights

The Ca(2+)-activated K(+) channel, K(Ca)3.1, is crucial for cell function and implicated in various diseases. This review examines K(Ca)3.1

Area of Science:

  • Physiology
  • Pharmacology
  • Molecular Biology

Background:

  • The Ca(2+)-activated K(+) channel K(Ca)3.1 plays a vital role in regulating membrane potential and calcium signaling.
  • K(Ca)3.1 is expressed in key cell types including erythrocytes, immune cells, endothelial cells, and smooth muscle cells.
  • Dysregulation of K(Ca)3.1 is linked to the pathology of diverse diseases like sickle cell anemia, asthma, and atherosclerosis.

Purpose of the Study:

  • To review the physiological and pharmacological properties of the K(Ca)3.1 channel.
  • To critically evaluate preclinical and clinical evidence supporting K(Ca)3.1 as a therapeutic target.
  • To explore the therapeutic potential of targeting K(Ca)3.1 for various human diseases.

Main Methods:

  • Comprehensive literature review of existing physiological and pharmacological data.
  • Analysis of preclinical studies investigating K(Ca)3.1 modulators.
  • Examination of available clinical trial data related to K(Ca)3.1 inhibition or activation.

Main Results:

  • K(Ca)3.1's established role in regulating cellular functions across multiple cell types.
  • Significant preclinical data supports K(Ca)3.1 as a viable therapeutic target for several diseases.
  • Emerging clinical data provides further validation, though more research is needed.

Conclusions:

  • K(Ca)3.1 is a key regulator of cellular processes implicated in disease.
  • The channel represents a promising therapeutic target with substantial preclinical and growing clinical support.
  • Further investigation into K(Ca)3.1 modulation is warranted for developing novel treatments.

More Related Videos

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting10:08

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...